A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 414
- Population
- ALL · 18 Years
- Duration
- 2021-12-01 to 2022-12-12
- Intervention
- Comparator
- Not reported
- Outcomes measured
- Mean change in injection interval from baseline to Month 12 for BRO and ALT cohorts — Baseline, Month 12; Change in injection interval from first brolucizumab injection to Month 18 for BRO and ALT cohorts — Baseline, Month 18; Change in visual acuity (VA) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and Month 18 (for…; Change in central macular thickness (CMT) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and M…; Age — Baseline; Gender — Baseline; Visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] Letters) — Baseline, Month 12 and Month 18; Anti-VEGF treatment status — Baseline; Last injection interval before switch to brolucizumab in prior-treated eyes — Baseline; Central macular thickness (CMT) — Baseline, Month 12 and Month 18; Intraretinal fluid (IRF) — Baseline; Subretinal fluid (SRF) — Baseline; Pigment epithelial detachment (PED) — Baseline; Number of brolucizumab injections and non-brolucizumab injections from first brolucizumab injection to 12 months (for A…; Ocular adverse events (AEs) in eyes treated with at least one brolucizumab injection — Up to 3 years; Median time (days) from first brolucizumab injection to AE — Up to 3 years; Median time (days) from last brolucizumab injection pre-AE to AE — Up to 3 years; Median time (days) from AE to resolution — Up to 3 years; Median number of brolucizumab injections pre-AE including the index injection — Up to 3 years; Proportion of patients in different levels of vision recovery after AE resolution — Up to 3 years
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.